NCT00325455终止2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of MK-0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 500
- 主要终点
- To assess the cholesterol changing effects of MK0859
研究概览
简要总结
To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible patients will be men and women of non-child bearing potential, 18 through 75 years of age diagnosed with high cholesterol
排除标准
- •Patients with CHD or CHD-equivalent disease (except diabetes)
- •Diabetics on statins
结局指标
主要结局
To assess the cholesterol changing effects of MK0859
次要结局
- Acceptable safety profile
研究者
相似试验
已完成
3 期
Effect of MK0524A on Cholesterol Levels (0524A-048)HypercholesterolemiaHyperlipidemiaNCT00536510Merck Sharp & Dohme LLC646
已完成
1 期
The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)DyslipidemiaNCT00990808Merck Sharp & Dohme LLC46
已完成
2 期
Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.DyslipidemiaNCT00326326Pfizer84
已完成
3 期
Lipid Efficacy/Tolerability Study (0524A-020)Primary HypercholesterolaemiaMixed HyperlipidaemiaNCT00269204Merck Sharp & Dohme LLC1,620
已完成
3 期
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)Coronary DiseaseHypercholesterolemiaNCT00092625Organon and Co442